Less Ads, More Data, More Tools Register for FREE

Pin to quick picksINS.L Regulatory News (INS)

  • There is currently no data for INS

Contract win

1 May 2014 07:00

RNS Number : 0079G
Instem plc
01 May 2014
 



 

 

Instem plc

("Instem" or the "Company")

 

Contract Win

 

Instem's Provantis and Centrus solutions selected by WIL Research to replace and enhance its toxicology systems and processes worldwide

 

Instem (AIM: INS.L), a leading provider of IT solutions to the global early development healthcare market, announces today that it has been selected by WIL Research ("WIL") as its exclusive non-clinical technology partner, to optimise study-related processes at all WIL worldwide sites.

 

Key Facts

· Instem technology to replace all existing study management systems at WIL Research

· WIL Research selects all Provantis Preclinical Study Management modules

· Using Instem's Centrus-submit solution, WIL Research will become SEND (Standard for Exchange of Nonclinical Data) enabled

· WIL Research to leverage Instem's market leading SaaS model for worldwide deployment

 

WIL Research has approximately 1,200 staff offering a blend of technical and regulatory expertise in discovery support, product safety toxicological research, metabolism, bioanalytical chemistry, analytical chemistry and formulation services.

 

WIL Research has chosen Instem's entire Provantis software suite, including its Logbook ELN solution for paper form replacement, as part of a multi-year project. Instem's Toxicology Resource Planning ("TRP") solution is also a key element of the Provantis deployment, increasing efficiencies by enabling WIL Research to plan and manage studies and programs, allocate resources, benchmark against past studies and plan workloads for the future.

WIL Research has additionally selected Instem's Centrus-submit™ solution to support SEND, the standardised reporting format for nonclinical data. The submit solution suite converts data from any source system into SEND files and allows sponsors, CROs and regulators such as the FDA to share, visualise and analyse study data more efficiently.

 

David Spaight, Chief Executive Officer at WIL Research, commented: "We are delighted to announce our enhanced partnership with Instem on a global level to deploy a comprehensive solution for toxicology data collection and management across our facilities situated in the United States, the Netherlands and in France. By leveraging our existing experience with Provantis in France, this expanded platform will support growing demand from our clients requiring a common and seamless multi-site global study management solution."

 

Phil Reason, CEO of Instem plc, commented: "WIL's selection of Instem's technology to replace all of its existing study management systems is a significant endorsement of the quality of our solutions. WIL has been a valued customer of Instem for 7 years and we are excited that it has chosen to extend that relationship as part of the technology-driven transformation that it is embarking upon. Instem has already secured SaaS revenues in excess of $2 million per annum and this provides further evidence of the attractiveness of this solution to clients. Demand for our offering remains strong and the growing proportion of SaaS contracts is leading to increasing visibility going forward."

 

 

 

 

 

 

For further information, please contact:

 

Instem plc

www.instem.com

Phil Reason, CEO

Tel: +44 (0) 1785 825 600

Nigel Goldsmith, CFO

 

 

 

N+1 Singer (Nominated Adviser & Broker)

Tel: +44 (0) 20 7496 3000

Richard Lindley

 

Nick Owen

 

 

 

Walbrook PR Ltd

Tel: +44 (0) 20 7933 8780 or instem@walbrookpr.com

Bob Huxford

Mob: +44 (0)7747 635 908

Helen Cresswell

Mob: +44 (0)7841 917 679

 

 

 

About WIL Research

WIL Research is an interdisciplinary non-clinical contract research organisation providing product safety and toxicological assessment research and services to the international pharmaceutical, biotechnology, chemical, agricultural, veterinary, food and consumer products industries.

 

Find out more about WIL Research at www.wilresearch.com

 

 

About Instem

Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutionsfor data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organisations for data-driven decision making leading to safer, more effective products.

 

Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledgethrough the extraction and harmonisation of actionable scientific information.

 

Instem supports over 400 clients through full service offices in the United States, United Kingdom and China with additional locations in India and a full service distributor based in Japan.

 

To learn more about Instem solutions and its mission, please visit www.instem.com.

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAQKKDBCBKDPQN
Date   Source Headline
29th May 20137:00 amRNSGlobal R&D Organisation selects Centrus & SRS
23rd May 20133:08 pmRNSResult of AGM
13th May 20137:00 amRNSAcquisition of Logos Technologies
26th Apr 20134:48 pmRNSPosting of Annual Report, Notice of AGM
23rd Apr 20136:20 pmRNSHolding(s) in Company
18th Apr 20137:00 amRNSCustomer Wins for New Provantis Release
27th Mar 20137:00 amRNSFinal Results
12th Mar 20137:00 amRNSNotice of Final Results
1st Mar 20133:25 pmRNSHolding(s) in Company
28th Feb 20137:00 amRNSUS Government Contract Win
30th Jan 20139:42 amRNSHolding(s) in Company
21st Jan 20137:00 amRNSHolding(s) in Company
10th Jan 20137:01 amRNSJOINN Laboratories China Purchases Provantis
10th Jan 20137:00 amRNSTrading Update
24th Dec 20127:00 amRNSTrading Update
18th Dec 20127:00 amRNSMulti-year Contract Extension & New Awards
3rd Dec 20127:00 amRNSCentrus Contract Win
7th Nov 20127:00 amRNSContract Win with US Government Research Agency
29th Oct 20127:00 amRNSChange of name of Nominated Adviser and Broker
19th Sep 20127:00 amRNSUnaudited Interim Results
5th Sep 20127:00 amRNSNotice of Interim Results
26th Jul 20127:00 amRNSTrading Update
25th Jul 20125:40 pmRNSHolding(s) in Company
22nd May 20123:46 pmRNSResult of AGM
8th May 201212:11 pmRNSPosting of Annual Report, Notice of AGM
24th Apr 20129:17 amRNSHolding(s) in Company
30th Mar 20124:52 pmRNSTotal Voting Rights and Capital
29th Mar 20122:49 pmRNSHolding(s) in Company
28th Mar 20127:00 amRNSFinal Results
26th Mar 20127:00 amRNSEstablishment of Instem India
8th Mar 20127:00 amRNSIssue of Equity and Director/PDMR Shareholding
20th Feb 20127:00 amRNSNotice of Final Results
9th Feb 20128:34 amRNSDirector/PDMR Shareholding
1st Feb 20129:14 amRNSAppointment of Nominated Adviser and Broker
18th Jan 20126:21 pmRNSChange of Name
9th Jan 20127:00 amRNSTrading Update
30th Nov 20113:57 pmRNSAppointment of CFO
21st Sep 20117:00 amRNSUnaudited Interim Results
10th Aug 20112:57 pmRNSNotification of Death of Director
4th May 20115:32 pmRNSPosting of Annual Report & Notice of AGM
22nd Mar 20117:00 amRNSFinal Results
4th Mar 20117:00 amRNSAcquisition of BioWisdom
19th Jan 20117:00 amRNSTrading Update
29th Oct 201011:34 amRNSTotal Voting Rights
19th Oct 20107:00 amRNSHolding(s) in Company
15th Oct 201010:38 amRNSHolding(s) in Company
13th Oct 20107:00 amRNSFirst Day of Dealings on AIM
19th Feb 20083:38 pmRNSDividend Declaration
15th Feb 200811:34 amRNSResults of GM
31st Jan 20083:28 pmRNSNotification of Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.